Point of Care Fertility Testing Market Size (2024-2030)

The Global Point of Care Fertility Testing Market was estimated to be worth USD 1.46 billion in 2022 and is projected to reach a value of USD 1.97 billion by 2030, growing at a CAGR of 4.4% during the forecast period 2023-2030.

The point of care a sort of medical test known as fertility testing can be carried out at or close to the location of the patient's treatment, such as at home, in a drugstore, or a clinic. People may keep track of their reproductive health and plan their pregnancies with the use of point-of-care fertility testing. Ovulation prediction kits, fertility monitors, sperm analyzers, and pregnancy tests are a few items used for point-of-care fertility testing.

Global Point of Care Fertility Testing Market Drivers:

One of the factors driving the need for point-of-care fertility testing products is the dropping fertility rate among men and women:

The average number of children a woman has over her lifetime is her fertility rate. Numerous elements, including biological, physiological, social, economic, and environmental ones, have an impact on them. Both men and women can have decreased fertility due to smoking, drinking, using drugs, being overweight, stress, and chronic illnesses. Smoking, for instance, may lower the quantity and quality of male sperm and raise the risk of infertility and miscarriage in females. Obesity can result in decreased sperm quality and erectile dysfunction in males and hormonal abnormalities and ovulation issues in women. Age causes a drop in fertility, notably after 35 for women and 40 for males. Pregnancies can be avoided or delayed by using contraception, sterilization, or abortion. Different nations and areas have different levels of these techniques' accessibility and efficacy. Due to social or personal factors, some people may decide to have fewer or no children.

The need for point-of-care fertility testing tools is being driven by the rising number of women who suffer from conditions including polycystic ovarian syndrome (PCOS):

Androgens, male sex hormones that are typically present in women at modest levels, are produced abnormally by the ovaries in PCOS. Along with other symptoms including irregular periods, excessive body hair, acne, weight gain, and insulin resistance, PCOS can impact ovulation and fertility. Due to irregular or absent ovulation, women with PCOS may have trouble becoming pregnant. A mature egg is released from an ovary during ovulation so that it may be fertilized by a sperm. Women with PCOS can track their ovulation patterns and recognize their fertile days with the use of point-of-care fertility testing equipment like ovulation prediction kits and fertility monitors. Pregnancy problems such as preterm delivery, gestational diabetes, and preeclampsia may be more common in women with PCOS. Women with PCOS can confirm their pregnancy status and keep an eye on their health during pregnancy with the use of point-of-care fertility testing tools like pregnancy tests and home blood pressure monitors.

Global Point of Care Fertility Testing Market Challenges:

Factors that are restraining the demand for fertility test kits may slower the growth of the market:

The fertility and pregnancy test business is fiercely competitive, with numerous well-established national and regional companies vying for market dominance. This can cause issues like confusion and issues with trust, which can cause customers to choose another brand of laboratory test instead. Additionally, doctors prefer laboratory diagnosis to home testing kits. Additionally, unreliable findings, such as false positive and negative results, deter some consumers from choosing home pregnancy tests. This lowers sales of the product and might prove to be a substantial market limitation for the quick test kits for the fertility and pregnancy product category. Lack of knowledge about fertility and pregnancy fast test kits, as well as being unable to purchase goods because of financial hardship, can also somewhat restrain the expansion of the worldwide market. The lack of uptake of these items in nations with market potential suggests that there are obstacles to market expansion.

COVID-19 Impact on Global Point of Care Fertility Testing Market:

COVID-19 has made an enduring impression on a variety of areas, including healthcare. The daily diagnostic test procedures have been hampered by supply shortages and postponed lab visits. As the demand for self-test kits (including midstream kits) and point-of-care kits increased, it was anticipated that the market for fertility and pregnancy quick test kits would expand dramatically. People chose to stay at home during the outbreak rather than go to hospitals, which is why this happened. For instance, Apollo Pharmacy reported a rise in Indian sales of over 50%. This rise was also related to COVID-19's usage of pregnancy quick test kits. Similarly to this, the market will keep "expanding, with sales of fertility and pregnancy fast test kits compelling players to rely on them more over the projection period.

Global Point of Care Fertility Testing Market Recent developments:

In June 2021: The distribution of particular diagnostics' REVEAL quick AST system by bioMérieux in Europe has strengthened the market for quick testing kits in the area of Europe.

POINT OF CARE FERTILITY TESTING MARKET REPORT COVERAGE:

Global Point of Care Fertility Testing Market Segmentation: By Type

• Human chorionic Gonadotropin (HCG) urine test

• FSH urine test

• Human chorionic Gonadotropin (HCG) blood test

• Luteinizing hormone (LH) urine test

One of the most precise and sensitive tests for detecting pregnancy is the human chorionic gonadotropin (HCG) urine test. It checks a person's urine's Human Chorionic Gonadotropin (HCG) levels to determine whether or not they are pregnant. Only during pregnancies does the HCG hormone become generated, therefore if you have any in your system, you're probably expecting. On the market, human chorionic gonadotropin (HCG) is the most popular product.

The urine test for luteinizing hormone (LH) is likely to expand at the quickest rate. The hormones LH, FSH, estrogen, and progesterone are all measured in a luteinizing hormone (LH) urine test, a kind of pregnancy and fertility testing. It may be used to determine infertility issues including polycystic ovarian syndrome as well as abnormal ovaries. This approach entails taking urine samples at particular intervals during your menstrual cycle for testing to see whether you are overproducing estrogen without releasing enough eggs from your ovaries or if you are experiencing other types of anovulation problems.

Global Point of Care Fertility Testing Market Segmentation: By Fertility Tests

• Line-Indicator

• Digital

The line-indicator tests are probably the area of the global point-of-care fertility testing market that is expanding the quickest. Traditional fertility tests that employ color-changing lines to show a woman's reproductive status are called "line-indicator" tests. The luteinizing hormone (LH) spike, which happens soon before ovulation, is frequently picked up by these tests. The LH surge signals a woman's most fertile time for conception.

Digital tests are most likely to be the most dominating section of the worldwide point-of-care fertility testing market. This is because digital testing is more convenient and user-friendly than line-indicator tests. The digital display eliminates the requirement for color line interpretation, lowering the possibility of mistakes. Digital testing: More up-to-date and offering a digital representation of reproductive status are digital fertility tests. The LH surge is still detected by these tests, but the results are presented in a clear digital format, such as "high fertility" or "peak fertility," which makes it simpler for consumers to understand the findings.

Global Point of Care Fertility Testing Market Segmentation: By Distribution Channel

• Hypermarkets & supermarkets

• Gynaecology & fertility clinics

• Pharmacy

• Online sales

In gynecology and reproductive clinics, point-of-care (POC) pregnancy and fertility tests are used to deliver quicker findings and guarantee that patients may obtain accurate diagnoses at their leisure. Both blood and urine tests can be used to identify pregnancy; they both yield the same results, but a urine test has the benefit of being simpler to collect.  Therefore, urine testing might save time for women who have trouble drawing blood.

Location of Care To identify pregnancies early on, supermarkets and hypermarkets provide pregnancy and fertility testing. By monitoring levels of the human chorionic gonadotropin (HCG) hormone, which surges quickly after implantation before it can be noticed by other procedures like blood tests or ultrasound scans, the tests offered to assist women understand the healthiness of their pregnancies.

Global Point of Care Fertility Testing Market Segmentation: By End-User

• Hospitals & Clinics

• Research Institutes

• Diagnostic Laboratories

This is because people seeking fertility testing and treatment usually contact hospitals and clinics first. One of the main end users of point-of-care fertility testing is hospitals and clinics. These medical clinics provide patients with a full range of reproductive health treatments, including fertility testing. They frequently have sections or clinics dedicated to fertility care that provide a variety of diagnostic and therapeutic alternatives for single people and couples dealing with reproductive problems.

Diagnostic laboratories are probably the sector of the worldwide point-of-care fertility testing market that is expanding the quickest. Diagnostic labs are specialized settings where a range of medical examinations, including fertility tests, are carried out. These labs use qualified specialists to analyze samples and deliver precise findings, along with cutting-edge diagnostic tools. Numerous fertility tests, including hormone level analysis, semen analysis, and genetic testing, may be provided by diagnostic laboratories.

Global Point of Care Fertility Testing Market Segmentation: By Region

• North America

• Europe

• Asia Pacific

• South America

• Middle East and Africa

About 88.2% of the market for North American fertility test kit sales were in the United States. The market for pregnancy and fertility fast test kits for confirming pregnancy increased as a result of the growth in birthrate, and this trend is anticipated to continue during the forecasted period in the United States. Additionally, the U.S. working class is a major factor in the demand for pregnancy and fertility fast test kits since they seldom see doctors unless there is an emergency, which supports the local market. About 36.8% of the market in Western Europe was accounted for by the U.K. The main variables influencing growth in the region include elements like rising demand for quick and self-testing kits, particularly among working women due to a lack of time, rising unintended pregnancy rates, and expanding reproductive issues. The demand for fertility and pregnancy quick test kits in the UK is rising due to an increased pool of informed females, improving technology in fertility and pregnancy rapid test kits, and ongoing initiatives. quick tests assist women in making early choices to confirm or rule out pregnancy.

Key Players:

1. Alere Inc.

2. Quidel Corporation

3. Prestige Brands Holdings, Inc.

4. Church & Dwight Co., Inc.

5. bioMérieux SA

6. Geratherm Medical AG

7. Abbott Laboratories

8. Procter & Gamble Co.

9. DCC Plc.

10. Swiss Precision Diagnostics GmbH